New Delhi: Dr Reddy’s Laboratories (DRL) has recently announced its wholly-owned subsidiary Promius Pharma has sold rights of cloderm cream and its authorised generic to EPI Health, LLC. “Promius Pharma, LLC, has sold its rights of Cloderm (clocortolone pivalate) cream, 0.1 per cent and its authorised generic to EPI Health, LLC, an affiliate of EPI Group, LLC,” DRL said in a statement.
Clocortolone is a topical steroid. It is used in the form of an ester, clocortolone pivalate, and applied as a cream. It is used for the treatment of dermatitis and is considered a medium-strength corticosteroid.
Ron Owens, President of EPI Health, said: “The addition of this product to our growing portfolio will support our ongoing efforts to build a successful prescription branded franchise in the US while contributing to EPI Health’s goal of becoming a leader in medical dermatology.”